Samil Pharmaceutical Co.,Ltd (000520.KS)
KRW 13130.0
(-3.95%)
KRW 13130.0
(-3.95%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 370.68 Billion KRW | 3.92% |
| 2022 | 356.7 Billion KRW | 57.55% |
| 2021 | 226.4 Billion KRW | 18.13% |
| 2020 | 191.66 Billion KRW | 4.23% |
| 2019 | 183.87 Billion KRW | 24.28% |
| 2018 | 147.94 Billion KRW | 9.21% |
| 2017 | 135.47 Billion KRW | 34.14% |
| 2016 | 100.99 Billion KRW | 1.7% |
| 2015 | 99.31 Billion KRW | -8.29% |
| 2014 | 108.29 Billion KRW | -6.41% |
| 2013 | 115.7 Billion KRW | 4.25% |
| 2012 | 110.99 Billion KRW | -8.42% |
| 2011 | 121.2 Billion KRW | -5.2% |
| 2010 | 127.84 Billion KRW | -0.85% |
| 2009 | 128.95 Billion KRW | 5.16% |
| 2008 | 122.62 Billion KRW | 28.25% |
| 2007 | 95.61 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 379.45 Billion KRW | 1.91% |
| 2024 Q1 | 372.33 Billion KRW | 0.45% |
| 2023 FY | 370.68 Billion KRW | 3.92% |
| 2023 Q1 | 359.89 Billion KRW | 0.9% |
| 2023 Q4 | 370.68 Billion KRW | -3.26% |
| 2023 Q3 | 383.18 Billion KRW | 2.9% |
| 2023 Q2 | 372.36 Billion KRW | 3.47% |
| 2022 Q2 | 272.83 Billion KRW | 12.77% |
| 2022 Q4 | 356.7 Billion KRW | 23.48% |
| 2022 Q3 | 288.86 Billion KRW | 5.87% |
| 2022 Q1 | 241.93 Billion KRW | 6.86% |
| 2022 FY | 356.7 Billion KRW | 57.55% |
| 2021 Q3 | 230.47 Billion KRW | 1.21% |
| 2021 FY | 226.4 Billion KRW | 18.13% |
| 2021 Q4 | 226.4 Billion KRW | -1.77% |
| 2021 Q1 | 195.38 Billion KRW | 1.95% |
| 2021 Q2 | 227.73 Billion KRW | 16.55% |
| 2020 Q4 | 191.66 Billion KRW | 2.46% |
| 2020 Q1 | 181.85 Billion KRW | -1.1% |
| 2020 Q2 | 184.36 Billion KRW | 1.38% |
| 2020 Q3 | 187.06 Billion KRW | 1.46% |
| 2020 FY | 191.66 Billion KRW | 4.23% |
| 2019 FY | 183.87 Billion KRW | 24.28% |
| 2019 Q4 | 183.87 Billion KRW | 0.38% |
| 2019 Q2 | 148.7 Billion KRW | 0.93% |
| 2019 Q1 | 147.33 Billion KRW | -0.41% |
| 2019 Q3 | 183.17 Billion KRW | 23.18% |
| 2018 Q3 | 150.97 Billion KRW | 10.39% |
| 2018 FY | 147.94 Billion KRW | 9.21% |
| 2018 Q1 | 134.58 Billion KRW | -0.66% |
| 2018 Q2 | 136.77 Billion KRW | 1.63% |
| 2018 Q4 | 147.94 Billion KRW | -2.01% |
| 2017 Q3 | 132.31 Billion KRW | 1.56% |
| 2017 FY | 135.47 Billion KRW | 34.14% |
| 2017 Q1 | 96.61 Billion KRW | -4.34% |
| 2017 Q4 | 135.47 Billion KRW | 2.39% |
| 2017 Q2 | 130.28 Billion KRW | 34.85% |
| 2016 FY | 100.99 Billion KRW | 1.7% |
| 2016 Q4 | 100.99 Billion KRW | -1.9% |
| 2016 Q3 | 102.94 Billion KRW | 1.73% |
| 2016 Q2 | 101.19 Billion KRW | 3.01% |
| 2016 Q1 | 98.23 Billion KRW | -1.08% |
| 2015 Q3 | 99.73 Billion KRW | -5.4% |
| 2015 Q1 | 108.47 Billion KRW | 0.17% |
| 2015 Q2 | 105.42 Billion KRW | -2.82% |
| 2015 FY | 99.31 Billion KRW | -8.29% |
| 2015 Q4 | 99.31 Billion KRW | -0.42% |
| 2014 Q2 | 114.61 Billion KRW | -1.54% |
| 2014 Q1 | 116.4 Billion KRW | 0.6% |
| 2014 FY | 108.29 Billion KRW | -6.41% |
| 2014 Q4 | 108.29 Billion KRW | -4.36% |
| 2014 Q3 | 113.22 Billion KRW | -1.21% |
| 2013 Q1 | 109.1 Billion KRW | -1.7% |
| 2013 FY | 115.7 Billion KRW | 4.25% |
| 2013 Q3 | 107.22 Billion KRW | -0.7% |
| 2013 Q2 | 107.97 Billion KRW | -1.03% |
| 2013 Q4 | 115.7 Billion KRW | 7.92% |
| 2012 Q4 | 110.99 Billion KRW | 0.0% |
| 2012 FY | 110.99 Billion KRW | -8.42% |
| 2012 Q1 | 118.2 Billion KRW | 0.0% |
| 2011 Q2 | 132.77 Billion KRW | -0.36% |
| 2011 Q3 | 128 Billion KRW | -3.59% |
| 2011 FY | 121.2 Billion KRW | -5.2% |
| 2011 Q1 | 133.24 Billion KRW | 4.22% |
| 2010 Q2 | 123.36 Billion KRW | 7.85% |
| 2010 FY | 127.84 Billion KRW | -0.85% |
| 2010 Q1 | 114.39 Billion KRW | -11.29% |
| 2010 Q4 | 127.84 Billion KRW | 2.01% |
| 2010 Q3 | 125.32 Billion KRW | 1.59% |
| 2009 Q2 | 121.87 Billion KRW | -2.38% |
| 2009 Q3 | 133.91 Billion KRW | 9.87% |
| 2009 Q1 | 124.85 Billion KRW | 1.82% |
| 2009 FY | 128.95 Billion KRW | 5.16% |
| 2009 Q4 | 128.95 Billion KRW | -3.7% |
| 2008 FY | 122.62 Billion KRW | 28.25% |
| 2008 Q2 | 118.4 Billion KRW | 6.01% |
| 2008 Q4 | 122.62 Billion KRW | -4.27% |
| 2008 Q3 | 128.09 Billion KRW | 8.18% |
| 2008 Q1 | 111.69 Billion KRW | 16.82% |
| 2007 Q3 | 100.04 Billion KRW | -1.14% |
| 2007 Q4 | 95.61 Billion KRW | -4.43% |
| 2007 FY | 95.61 Billion KRW | 0.0% |
| 2007 Q1 | 95.89 Billion KRW | 0.0% |
| 2007 Q2 | 101.19 Billion KRW | 5.53% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -87.01% |
| Dong-A Socio Holdings Co., Ltd. | 1957.1 Billion KRW | 81.06% |
| Ildong Holdings Co., Ltd. | 876.99 Billion KRW | 57.733% |
| HANDOK Inc. | 790.33 Billion KRW | 53.099% |
| Kukje Pharma Co., Ltd. | 170.61 Billion KRW | -117.255% |
| Yuhan Corporation | 2814.07 Billion KRW | 86.828% |
| Dong-A ST Co., Ltd. | 1315.21 Billion KRW | 71.816% |
| SAMSUNG PHARM. Co., LTD. | 93.47 Billion KRW | -296.538% |
| Hanmi Pharm. Co., Ltd. | 1952.03 Billion KRW | 81.011% |
| Hanall Biopharma Co.,Ltd | 239.74 Billion KRW | -54.613% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 20.947% |
| Dong Sung Bio Pharm.Co.,Ltd. | 114.97 Billion KRW | -222.405% |
| MYUNGMOON Pharm co.,Ltd | 236.54 Billion KRW | -56.703% |
| Hana Pharm Co., Ltd. | 348.38 Billion KRW | -6.399% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -87.01% |
| Ilsung Pharmaceuticals Co., Ltd. | 419.18 Billion KRW | 11.572% |
| REYON Pharmaceutical Co., Ltd. | 499.77 Billion KRW | 25.831% |
| Aprogen pharmaceuticals,Inc. | 589.39 Billion KRW | 37.109% |
| JW Holdings Corporation | 1176.26 Billion KRW | 68.487% |
| Ildong Pharmaceutical Co., Ltd. | 611.26 Billion KRW | 39.358% |
| Chong Kun Dang Pharmaceutical Corp. | 1402.42 Billion KRW | 73.569% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 42.534% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -5.883% |
| Hyundai Pharmaceutical Co., Ltd. | 154.04 Billion KRW | -140.637% |
| Jeil Pharmaceutical Co.,Ltd | 487.32 Billion KRW | 23.936% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -87.01% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1078.06 Billion KRW | 65.616% |
| Daewoong pharmaceutical Co.,Ltd | 1770.31 Billion KRW | 79.061% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 42.534% |
| Yuhan Corporation | 2814.07 Billion KRW | 86.828% |
| Jeil Pharma Holdings Inc | 879.99 Billion KRW | 57.877% |
| Yungjin Pharm. Co., Ltd. | 226.6 Billion KRW | -63.583% |
| Suheung Co., Ltd. | 993.73 Billion KRW | 62.698% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 42.534% |
| Samjin Pharmaceuticals Co., Ltd. | 419.9 Billion KRW | 11.722% |
| Korea United Pharm Inc. | 468.86 Billion KRW | 20.94% |
| CKD Bio Corp. | 293.78 Billion KRW | -26.174% |
| Daewon Pharmaceutical Co., Ltd. | 507.99 Billion KRW | 27.031% |
| Dongwha Pharm.Co.,Ltd | 564.97 Billion KRW | 34.39% |
| Whan In Pharm Co.,Ltd. | 401.22 Billion KRW | 7.613% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -5.883% |
| Chong Kun Dang Holdings Corp. | 1456 Billion KRW | 74.541% |
| Boryung Corporation | 922.36 Billion KRW | 59.812% |
| Bukwang Pharmaceutical Co., Ltd. | 442.46 Billion KRW | 16.223% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 20.947% |
| JW Lifescience Corporation | 255.83 Billion KRW | -44.89% |